Manages pharmaceutical collaborations for antibody medicines used in cancer and inflammatory diseases.
10-K for FY2025, filed Mar 3, 2026We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory…View ↗
In September 2025, we announced that our board of directors (“Board of Directors”) approved plans to explore separating our business into…View ↗
Multiple company-discovered antibody programs have been advanced to preclinical and clinical milestones under our collaborations. Our…View ↗
On January 31, 2025, we entered into an Exclusive License Agreement (the “Vanda License Agreement”) with Vanda pursuant to which we granted…View ↗
Receives royalties and milestone payments tied to Jemperli under the GSK collaboration. Vanda paid an upfront license fee and drug-supply payment for imsidolimab; Anaptys may also receive sales royalties and milestone payments, plus license and transition-service revenue.
10-K for FY2025, filed Mar 3, 2026
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by reportable segment ↗$234.6M
10-K for FY2025, filed Mar 3, 2026
$234.6M ↗| Segment | Share | Revenue |
|---|---|---|
|
Biopharma
|
0.0% |
Biopharma, FY2025
$0 Sources
|
|
Royalty Management
|
100% |
Royalty Management, FY2025
$234.6M Sources
|
Pharmaceutical partners GSK and Vanda contract with Anaptys through collaborations and licenses; Vanda holds an exclusive global license for imsidolimab.
10-K for FY2025, filed Mar 3, 2026
10-Q for Q1 FY2027, filed Nov 12, 2026
Open tableView ↗
8-K, filed May 11, 2026
Appointment of Chief Financial OfficerView ↗
8-K, filed Apr 20, 2026
SAN DIEGO, CA — April 20, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its…View ↗
8-K, filed Mar 27, 2026
Company to launch with $180 million in cash and an initial two-year cash-runwayView ↗
Growing. Revenue grew 3.7x in 4 years, from $63.2M in FY2021 to $234.6M in FY2025, about 39% a year.
Imsidolimab licensing
The earlier report said Anaptys was exploring an out-license for imsidolimab; the newer report says it granted Vanda an exclusive global license and earned license and transition-service revenue from the collaboration.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 3, 2026We announced in August 2022 that we intend to complete execution of our Phase 3 program in GPP and out-license imsidolimab prior to…View ↗
Competes with Gilead, Seismic Therapeutics, Abbvie, Roche, Regeneron, BMS, Eli Lilly, Pfizer, Forte Bioscience, Novartis, Teva, Biogen, Dianthus Therapeutics, and Amgen
10-K for FY2025, filed Mar 3, 2026For rosnilimab, our competitors include non-depleting PD-1 agonist antibodies GS-0151, (Gilead) in Phase 1b development for the treatment…View ↗
Loading...